Summit Therapeutics (SMMT) Announces CFO Resignation

On April 2, 2024, Ankur Dhingra, the principal financial officer and principal accounting officer of Summit Therapeutics (NASDAQ: SMMT), resigned as Chief Financial Officer of the Company. Mr. Dhingra’s resignation was not due to any disagreement with the Company relating to its operations, policies or practices.

In order to replace Mr. Dhingra, contemporaneously with Mr. Dhingra’s resignation, the Company appointed its Chief Operating Officer Manmeet Soni to the office of Chief Financial Officer, in which capacity he will serve as the Company’s principal financial officer, in addition to his continuing service as Chief Operating Officer. As compensation for Mr. Soni’s acceptance of the additional responsibility of serving as the Company’s principal financial officer, in addition to his existing compensation, he will receive a one-time cash bonus in the amount of $100,000 and 1,100,000 options to purchase shares of the Company’s common stock (“Common Stock”). The options granted to Mr. Soni shall vest in equal annual installments over a four-year period.

You May Also Be Interested In

• Datavault AI names Arqit co-founder as chief security officer
• H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
• ASP Isotopes (ASPI) files for 23.16M share offering by selling stockholders